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ABSTRACT
Objective: There is currently limited information regard-
ing the out-of-pocket expenditures (OOPE) for medical
care made by elderly individuals with cancer. We sought
to quantify OOPE for community-dwelling individuals
age 70 or older with: 1) no cancer (No CA), 2) a history
of cancer, not undergoing current treatment (CA/No Tx),
and 3) a history of cancer, undergoing current treatment
(CA/Tx).
Methods: We used data from the 1995 Asset and
Health Dynamics Study, a nationally representative
survey of community-dwelling elderly individuals.
Respondents identiﬁed their cancer status and reported
OOPE for the prior 2 years for: 1) hospital and nurs-
ing home stays, 2) outpatient services, 3) home care,
and 4) prescription medications. Using a multivariable
two-part regression model to control for differences in
sociodemographics, living situation, functional limita-
tions, comorbid chronic conditions, and insurance cov-
erage, the additional cancer-related OOPE were
estimated.
Results: Of the 6370 respondents, 5382 (84%) reported
No CA, 812 (13%) reported CA/No Tx, and 176 (3%)
reported CA/Tx. The adjusted mean annual OOPE for the
No CA, CA/No Tx, and CA/Tx groups were $1210,
$1450, and $1880, respectively (P < .01). Prescription
medications ($1120 per year) and home care services
($250) accounted for most of the additional OOPE asso-
ciated with cancer treatment. Low-income individuals
undergoing cancer treatment spent about 27% of their
yearly income on OOPE compared to only 5% of yearly
income for high-income individuals with no cancer his-
tory (P < .01).
Conclusions: Cancer treatment in older individuals
results in signiﬁcant OOPE, mainly for prescription med-
ications and home care services. Economic evaluations
and public policies aimed at cancer prevention and treat-
ment should take note of the signiﬁcant OOPE made by
older Americans with cancer.
Keywords: cancer, cost of illness, elderly, health-care
expenditures, health economics.
Introduction
Although nearly all individuals age 65 or older in
the United States are eligible for health insurance
beneﬁts from the federal Medicare program, cover-
age limitations may result in large additional out-
of-pocket expenditures (OOPE) for deductibles,
copayments, and uncovered services [1–3]. The
increasing OOPE incurred by Medicare beneﬁciar-
ies has spurred intense political debate regarding
extending Medicare coverage to previously uncov-
ered services such as prescription medications and
long-term care [3–5]. Underlying this debate is the
concern that large OOPE may result in decreased
access to necessary health-care services [6]
decreased use of effective medications [7–9] and,
ultimately, decreased health status and quality of
life for older Americans, especially those with low
income [10].
The increasing number of elderly individuals
with chronic health conditions [11,12] are at espe-
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cially high risk of having signiﬁcant OOPE owing to
their greater use of health-care services and medica-
tions [3]. Cancer is a common cause of morbidity
and mortality among elderly individuals and there-
fore may lead to signiﬁcant health-care utilization
and OOPE. In fact, cancer is the most common
cause of death in older women and is roughly equal
to heart disease as the leading cause of death in men
[13,14]. Total cancer-related costs in the United
States may approach $100 billion per year [15].
A number of studies have examined the direct
medical costs associated with cancer [16–26], but
these studies did not identify the OOPE that
patients and families incur. Although other studies
have focused more closely on OOPE for cancer
patients, few have examined expenditures for eld-
erly cancer patients [17,27–34]. In addition, most
prior studies have used patient data from small geo-
graphically restricted samples and focused on a
single cancer type, raising concerns about the gen-
eralizability of ﬁndings.
Given the growing importance of cancer among
elderly individuals and the potential for signiﬁcant
increases in the OOPE related to a cancer diagnosis,
we undertook this study to provide valid and gen-
eralizable estimates of the OOPE associated with
cancer in older Americans. Our aim was to identify
the additional OOPE owing to cancer, as opposed
to the expenditures for other comorbid conditions.
In addition, we chose to examine four important
cost categories separately so as to better identify the
determinants of OOPE among older individuals, in
general, and older individuals with cancer, in
particular.
Methods
Data
We used the 1995 Asset and Health Dynamics
among the Oldest Old (AHEAD) cohort of the
Health and Retirement Study (HRS) for this analy-
sis. The HRS is a nationally representative biennial
longitudinal survey conducted by the Institute for
Social Research at the University of Michigan with
funding from the National Institute on Aging.
AHEAD respondents included 7443 men and
women 70 years of age or older at the time of the
baseline interview in 1993 (i.e., born in 1923 or
before). Interviews were conducted in person or
over the telephone in English or Spanish. Proxy
respondents were interviewed in cases where the
selected respondents were unable to answer the sur-
vey questions independently. A response rate of
80.4% was achieved [35].
The 1995 AHEAD survey included a sample of
6644 respondents aged 70 or older who were rep-
resentative of the approximately 23 million elderly
individuals in the United States in 1995. For this
study, we excluded 264 respondents (4%) who were
living in a nursing home at the time of the interview
and 10 respondents (0.1%) who had missing data
necessary for the analyses. The ﬁnal study sample of
community-dwelling individuals age 70 or older
consisted of 6370 respondents.
Determining OOPE
In the AHEAD study, respondents were asked to
report the extent of their insurance coverage and
their OOPE for four categories of health-care serv-
ices: 1) hospital and nursing home stays; 2) outpa-
tient services, such as doctor visits, dental visits, and
outpatient surgery; 3) home care or other commu-
nity-based “special services”; and 4) prescription
medications. For each of the ﬁrst three categories,
the survey question was phrased, “About how
much did you pay out of pocket for [hospital/doctor
visit/home care] bills in the last two years?” For pre-
scription medications, the question was phrased,
“On the average, about how much have you paid
out of pocket per month for prescription medica-
tions in the last two years?” Responses were con-
verted to average yearly expenditures for each of the
categories, and total average yearly expenditures
per individual were calculated by summing the
expenditures for each of the four categories.
The AHEAD survey uses an innovative “brack-
eting” method to collect data that are usually sub-
ject to high rates of nonresponse, such as health-
care expenditures [36]. When a respondent is
unwilling to provide an exact amount in response to
one of the expenditure questions, he/she is pre-
sented with response brackets such as, “Was it more
than $200?”; “more than $500?”; “less than
$1000?”; etc. The responses to these bracket ques-
tions are then used to impute an expenditure value
for these questions that can then more easily be used
in data analyses. Imputed responses for bracketed
questions were derived for between 2% (home care
expenditures) and 19% (doctor visits) of respond-
ents for the individual expenditure categories. The
full methodology for this imputation procedure is
described elsewhere [37].
Deﬁning Cancer and Cancer Treatment History
All AHEAD respondents were asked, “Has a doctor
ever told you that you have cancer or a malignant
tumor, excluding minor skin cancers?” All respond-
ents who answered “yes” to this question, were
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then asked, “Are you now receiving treatment for
cancer?” Based on their responses to these two
questions, respondents were sorted into three mutu-
ally exclusive categories: 1) no history of cancer (No
CA); 2) history of cancer, but no current treatment
(CA/No Tx); and 3) history of cancer, currently
receiving treatment (CA/Tx).
Household Net Worth and Yearly Income
The AHEAD study collects detailed ﬁnancial infor-
mation regarding total household net worth and
current yearly income. Both measures were exam-
ined in this analysis because yearly income may pro-
vide an inadequate measure of ﬁnancial status for
older individuals if they are retired from the labor
force. Net worth was deﬁned as total household
assets, including housing equity, stocks, bonds, sav-
ings accounts, and other assets, minus current debts
[35]. We deﬁned net worth terciles (low, middle,
high) to describe the level of wealth of an individ-
ual’s household. Yearly household income was
deﬁned as the total of all sources of income over the
prior year, including income from work, Social
Security beneﬁts, private pensions, and other invest-
ments [35]. Because the AHEAD study calculated
yearly income on a household level and OOPE on
an individual level, we divided household income by
two for married couples to obtain an estimate of per
capita yearly income. We constructed per capita
yearly income quartiles when performing analyses
of OOPE as a proportion of yearly income. As in
prior studies of OOPE [2,10] for this analysis,
OOPE were capped at 100% of yearly income to
decrease the inﬂuence of outlier values for OOPE on
the calculated ratios.
Health Insurance Coverage
In addition to coverage by the Medicare and/or
Medicaid government health insurance programs,
the AHEAD study identiﬁed whether individuals
obtained supplemental health insurance coverage
(e.g., “Medi-Gap” insurance) through a current or
former employer, an organization, or the private
insurance market. Enrollment in a Medicare HMO
was also identiﬁed. Because supplemental health
insurance plans, enrollment in a Medicare HMO,
and coverage under Medicaid may have a signiﬁ-
cant impact on the level of OOPE for health-care
services, we included these insurance variables in
our regression analyses.
Potential Confounding Variables
Because the goal of the analysis was to quantify the
additional OOPE attributable to a cancer diagnosis
and cancer treatment, we controlled for the pres-
ence of other factors that might independently
affect the likelihood and/or level of OOPE. The var-
iables controlled for in the analysis were self-
reported chronic health conditions (heart disease,
stroke, diabetes, hypertension, lung disease, psychi-
atric problem, and arthritis); the presence of cog-
nitive impairment consistent with dementia as
measured by a previously validated cognitive status
instrument [38,39]; the number of reported limita-
tions in activities of daily living (ADLs) (eating,
transferring, toileting, dressing, bathing, walking
across a room) and instrumental activities of daily
living (IADLs) (preparing meals, grocery shopping,
making phone calls, taking medications, manag-
ing money); sociodemographic characteristics (age,
race, sex, net worth); and living situation (married,
unmarried living alone, unmarried living with oth-
ers). The presence of supplemental insurance cover-
age, enrollment in a Medicare HMO, and coverage
by Medicaid were also included as independent var-
iables in the regression analyses.
Data Analysis
Because a substantial proportion of respondents
had no OOPE for some of the individual expendi-
ture categories, for example, approximately 90% of
respondents reported no OOPE for hospital or
nursing home care, and because the distribution of
expenditures was highly skewed, we used a two-
part multivariable regression model [40]. For the
ﬁrst part, we used logistic regression to determine
the relationship of cancer category (No CA, CA/No
Tx, or CA/Tx) to the likelihood of reporting any
OOPE, adjusting for the above potentially con-
founding factors. For the second part, we used ordi-
nary least squares linear regression to examine the
association between cancer category and the natural
log of OOPE among those who reported any
OOPE, again adjusting for the same potentially
confounding factors. The results from the two parts
of the model were then combined to obtain an esti-
mate of the unconditional effect (i.e., not condi-
tioned on having any OOPE) of cancer category on
OOPE. For ease of reporting and interpretation, the
results from the regression analyzes were retrans-
formed to whole dollar yearly expenditures [41].
Analyses were weighted and adjusted for the com-
plex sampling design of the AHEAD study. We tested
for signiﬁcant interaction effects among the inde-
pendent variables and performed regression diag-
nostics to check for inﬂuential observations and
heteroscedasticity in the residuals. All analyses were
performed using STATA Statistical Software (release
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7.0, 2001, Stata Corporation, College Station, TX).
The HRS/AHEAD study was approved by an insti-
tutional review board at the University of Michigan.
The data used for this analysis contained no unique
identiﬁers so respondent anonymity was maintained.
Results
Characteristics of  the Sample
Of the 6370 community-dwelling individuals age
70 or older in the 1995 AHEAD study, 5382 (84%)
reported no history of cancer, 812 (13%) reported a
history of cancer but no current treatment, and 176
(3%) reported a history of cancer and current treat-
ment. The characteristics of these three groups are
shown in Table 1. Those with a history of cancer
were more likely to be white and male, but there
was no signiﬁcant difference between those with
and without cancer in age, net worth, or living sit-
uation. Those undergoing cancer treatment were
less likely to be in the bottom income quartile than
either of the other two groups. Those with a history
of cancer were more likely to report one or more
ADL limitations. The presence of comorbid chronic
conditions was relatively similar across all three cat-
egories with arthritis, hypertension, and heart dis-
Table 1 Characteristics of  the study population, by cancer category (N = 6370)
Variable
Weighted percentage* 
No cancer
(n = 5382)
Cancer, no
current
treatment
(n = 812)
Cancer, 
current 
treatment 
(n = 176) P value
Age, years (mean ±SD) 79.6 ± 0.1 79.9 ± 0.2 80.1 ± 0.5
70–79 56 53 50 .1
80–89 38 41 43
≥90 6 6 7 .3
Race
White 90 94 94
African-American 9 5 5
Other 2 1 1 <.001
Sex
Male 39 44 57 <.001
Female 61 56 43
Net worth (US$)
<38,000 45 41 37
38,000–139,000 22 25 29 .2
>139,000 33 34 35
Yearly income
Bottom quartile 23 18 14
Second quartile 25 24 24 <.001
Third quartile 25 28 29
Top quartile 26 30 33
Living situation
Married 36 36 28
Unmarried living w/others 13 13 10 .1
Unmarried living alone 51 51 62
ADL limitations
0 68 64 62
1–3 25 28 33 .05
4–6 7 8 5
IADL limitations
0 77 77 73
1–3 19 17 24 .09
4–5 5 6 3
Chronic conditions
Heart disease 34 37 38 .3
Stroke 11 12 12 .3
Diabetes 14 14 15 .9
Hypertension 52 50 48 .4
Dementia 9 7 8 .3
Lung disease 11 13 12 .09
Psychiatric problem 11 13 9 .2
Arthritis 54 55 53 .8
Insurance status
Medicare 99 99 99 .9
Medicare HMO 13 14 13 .8
Supplemental insurance 67 71 69 .1
Medicaid 9 6 8 .04
*Weighted percentage derived using the AHEAD respondent population weights to adjust for the complex sampling design of  the AHEAD survey.
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ease most prevalent. There was a trend toward a
higher probability of supplemental insurance cover-
age among those with cancer, whereas those with
cancer not currently undergoing treatment had a
slightly lower probability of Medicaid coverage
than the other two groups.
Unadjusted OOPE
The great majority of individuals (86%) had some
type of OOPE. The number and percentage of
respondents reporting OOPE for each of the
expenditure categories is shown in Table 2. The
mean total OOPE ranged from $1370 for those in
the No CA category to $2100 in the CA/Tx cate-
gory (P < .05). The median total OOPE was less
than the mean OOPE for each cancer category, sug-
gesting that the distribution of total OOPE was
skewed right-ward with relatively few respondents
having very large OOPE.
Among the individual expenditure categories,
respondents in the CA/Tx category were more likely
those in the No CA category to have OOPE for
hospital/nursing home services (P < .01) and for
prescription medications (P < .01). Among those
reporting any OOPE in each of the individual
expenditure categories, the mean unadjusted OOPE
for the CA/Tx group were generally higher for each
expenditure category, except home care services.
Although the difference in unadjusted mean OOPE
for total expenditures was signiﬁcantly greater for
those undergoing current cancer treatment (P < .05),
the differences across cancer categories for the indi-
vidual expenditure types were not statistically sig-
niﬁcant, likely owing to the much smaller sample
sizes for the individual expenditure categories.
OOPE as a Percentage of  Yearly Income
Total unadjusted OOPE as a percentage of yearly
income, by cancer category, is shown in Figure 1.
Within each cancer category, the percentage of
yearly income that went to OOPE was inversely
related to income (P < .01). For individuals with no
history of cancer, OOPE as a percentage of yearly
income ranged from 5% for those in the top income
quartile to 17% for those in the bottom income
quartile. When looking across the three cancer cat-
egories, there was a trend toward an increasing per-
centage of yearly income going toward OOPE based
on cancer status, as the percentage increased from
17% among low-income individuals with no cancer
history to 27% for those currently undergoing can-
cer treatment (P < .07).
Adjusted OOPE
After adjusting for all other control variables using
the two-part regression model, the mean yearly
total OOPE for the No CA category was $1210 per
year (95% CI $1180–$1240) whereas for the CA/
Table 2 Unadjusted yearly OOPE among those reporting any expenditures, by expenditure type and cancer category (N = 6370)
Expenditure type
No cancer
(n = 5382)
Cancer, no current
treatment (n = 812)
Cancer, current 
treatment (n = 176)
Total expenditures
Number 4593 743 156
%† 86 92 89
Mean ±SD* $1370 ± $3440 $1560 ± $3700 $2100 ± $4770
Median $570 $640 $920
Hospital/nursing home
Number 511 104 29
%† 10 14 16
Mean ±SD $1090 ± $2580 $860 ± $1340 $1680 ± $3910
Median $370 $370 $370
Prescription medications
Number 3456 578 128
%† 66 72 74
Mean ±SD $1200 ± $3200 $1410 ± $3960 $1390 ± $4010
Median $470 $480 $490
Outpatient services
Number 3699 598 117
%† 70 75 67
Mean ±SD $360 ± $670 $380 ± $550 $670 ± $1420
Median $160 $180 $270
Home care services
Number 232 36 19
% 5 5 11
Mean ±SD $1310 ± $5500 $800 ± $1940 $1170 ± $2380
Median $100 $280 $100
*P < .05 for difference across cancer categories in mean total expenditures. Differences across cancer categories in means for individual expenditure types were not sta-
tistically signiﬁcant.
†P < .05 for difference across cancer categories in proportion of  respondents having any OOPE.
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No Tx category it was $1450 per year (95% CI
$1420–$1480), and for the CA/Tx category it was
$1880 per year (95% CI $1840–$1920) (P < .01)
(Fig. 2). So the OOPE of those with a prior cancer
diagnosis were 20% greater ($240 per year) than
those with no cancer history, and 55% greater
($670 per year) among those undergoing current
treatment for cancer.
When separating the total expenditures by indi-
vidual expenditure type, we found that prescription
medications were the main source of increased
OOPE among those undergoing cancer treatment.
Of the $670 additional total OOPE among those in
the CA/Tx group, $320 (48%) was attributable to
greater prescription medication expenditures.
Those in the No CA group averaged $800 per year
in OOPE for prescription medications, which
accounted for 66% of their total OOPE. Those in
the CA/No Tx group had $930 in OOPE for med-
ications (64% of total), whereas those in the CA/Tx
group had $1120 in OOPE for medications (60% of
total) (P < .05).
Those undergoing cancer treatment also had sig-
niﬁcantly higher hospital/nursing home expendi-
tures than those in the other two groups ($210
per year vs. $100 and $150 per year, respectively,
P < .05), although the absolute difference in OOPE
across groups for this expenditure category was not
as great as for prescription medications. OOPE for
outpatient services were relatively similar across
the three categories, whereas OOPE for home care
or “special services” were more than three times
greater among those undergoing cancer treatment
compared to the other two groups (P < .05).
Discussion
In this nationally representative sample of older
Americans, we found that a prior history of cancer
was associated with an additional $240 per year in
OOPE, whereas current cancer treatment was asso-
ciated with an additional $670 per year in OOPE,
even after controlling for differences across these
groups in sociodeomographics, living situation,
functional limitations, comorbid chronic condi-
tions, and insurance coverage. When translating
these ﬁndings to a national level using prevalence
estimates from the AHEAD study, individuals age
70 or older with a history of cancer made $700 mil-
lion ($240/person ¥ 2.9 million people) in addi-
tional yearly OOPE in 1995 compared to those with
no history of cancer, whereas those undergoing can-
cer treatment made an additional $400 million
($670/person ¥ 600,000 people) in OOPE.
Older individuals undergoing cancer treatment
had signiﬁcantly greater prescription medication
expenditures than those without a cancer history.
We hypothesize that prescription medications to
address common symptoms and side effects of can-
cer and its treatment (e.g., nausea, pain, and infec-
tions) and oral hormonal agents were the main
cause for increased OOPE for medications among
those undergoing cancer treatment. The AHEAD
study did not collect information on the speciﬁc
medications that individuals used, so we were una-
ble to determine the number and type of medica-
tions that resulted in increased OOPE for those
undergoing cancer treatment. The increased OOPE
for home care services were likely the result of both
increased utilization of postacute home care services
after hospitalizations for cancer treatment or com-
plications, as well as long-term home care services
Figure 1  Total out-of-pocket expenditures as a percentage of  yearly
income, by income quartile and cancer category. OOPE, out-of-
pocket expenditures; No CA, no cancer; CA/No Tx, cancer, not
undergoing current treatment; and CA/Tx, cancer, undergoing cur-
rent treatment. P < .01 for difference in OOPE as a percentage of
yearly income across income quartiles within each cancer category.
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Figure 2 Adjusted yearly out-of-pocket expenditures, by expendi-
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not undergoing current treatment; and CA/Tx,  cancer, undergoing
current treatment. “Outpatient” includes doctor visits, dental visits,
and outpatient surgery. NH, nursing home. P < .01 for difference in
adjusted yearly total OOPE across cancer categories.
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to address the greater level of ADL and IADL lim-
itations that were present among older individuals
undergoing cancer treatment.
Payments for hospital and/or nursing home care
were also greater among those undergoing cancer
treatment. Although the AHEAD data do not allow
expenditures for these two types of services to be
separated, we performed a secondary analysis that
showed that individuals undergoing cancer treat-
ment were more likely to be hospitalized at least
once in the prior 2 years (56% vs. 31% for those
with no cancer history, P < .01) and, among those
hospitalized the mean number of days in the hospi-
tal, was signiﬁcantly greater (15 days vs. 10 days,
P < .01). Conversely, the likelihood of short- or
long-term nursing home stays was similar for those
in both the No CA and the CA/Tx groups. This sug-
gests that payments for acute care hospital services,
not short- or long-term nursing home stays,
accounted for the signiﬁcantly greater OOPE for
those undergoing cancer treatment.
We expect that the greater utilization of hospital
services, and the greater associated OOPE for these
services, among those undergoing cancer treatment
was likely due to a number of factors including: 1)
acute complications related to cancer and subse-
quent inpatient evaluation and treatment for these
complications; 2) cancer treatments provided in the
inpatient setting (e.g., surgery); and 3) hospitaliza-
tions for complications related to cancer treatment.
The higher risk for multiple hospital stays related to
cancer treatment and its complications may be an
important contributor to the greater OOPE that we
found for older individuals undergoing treatment.
Currently, individuals covered by Medicare hospital
insurance (Part A) pay a deductible of $876 for each
hospital stay of 1 to 60 days during a beneﬁt period.
There is an additional copayment of $219 per day
for hospital days 61 through 90 [42]. So multiple
hospital stays for cancer treatment or complications
might quickly lead to signiﬁcant OOPE for older
cancer patients.
Prior studies have shown that older individuals
with high OOPE may restrict their use of effective
prescription medications [7,8]. Our ﬁndings raise a
related question as to whether older cancer patients,
especially those with low income, might forgo
potentially beneﬁcial treatments owing to concerns
over the high OOPE that may be associated with
them. We found a positive association between
higher levels of income and current cancer treat-
ment in the AHEAD cohort, and we also found that
low-income individuals undergoing cancer treat-
ment spent more than one-fourth of their yearly
income on their medical care compared to only 7%
for those in the upper quartile of income. Future
research should examine the extent to which the
ﬁnancial burden associated with cancer treatment
affects the decisions of both older patients and their
physicians when considering cancer therapy.
The major strength of the AHEAD study is its
large nationally representative sample of older
Americans that allows results to be generalized
with greater conﬁdence. Nevertheless, our ﬁndings
should be interpreted with a number of potential
limitations of these data in mind. First, because
AHEAD is a population-based cohort rather than a
treatment-based cohort, the number of individuals
who reported cancer treatment is relatively small. In
addition, data on the primary site of the cancer, as
well as treatment type, were not available, so we
were unable to identify expenditure differences
related to type of cancer or mode of treatment. Fur-
thermore, we did not have clinical information such
as cancer stage, whether the cancer was a new diag-
nosis or a recurrent diagnosis, and whether treat-
ment was intended to be curative or palliative.
Although this clinical information was not availa-
ble, the self-reported prevalence of cancer in this
AHEAD sample (15,600 cases per 100,000 individ-
uals) is nearly equivalent to the national prevalence
of cancer predicted by Surveillance, Epidemiology,
and End Results (SEER) data for individuals age 70
or older (15,800 cases per 100,000 individuals)
[43], suggesting that AHEAD does provide an accu-
rate assessment of cancer history in this age cohort.
A second limitation of our study is the lack of
medical claims data to verify the self-reported
OOPE in AHEAD. Ideally, expenditures reported
by individuals would be matched and cross-checked
with medical claims information to minimize both
under- and overreporting of medical utilization and
OOPE [44]; in the absence of such veriﬁcation, it is
difﬁcult to determine both the magnitude and the
direction of potential reporting inaccuracies for
OOPE within our sample. Nevertheless, compari-
sons of the AHEAD OOPE data to that reported in
prior studies that relied on both self-report and
claims data show comparable results. For instance,
the Medicare Current Beneﬁciary Survey (MCBS), a
survey that cross-checks self-reported OOPE with
Medicare claims [2], found that the mean 1995
total OOPE for individuals age 65 or older ranged
from approximately $1400 for those with no
chronic conditions to $2100 for those with three to
ﬁve chronic conditions, similar to our ﬁndings using
AHEAD data, although direct comparison to the
MCBS is difﬁcult owing to differences in the cate-
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gories of services and payments that are included in
the OOPE totals [2,10]. The 1995 MCBS data also
conﬁrm our ﬁndings of increased OOPE among
older individuals with a history of cancer, as those
reporting a cancer history not necessarily with cur-
rent treatment in the MCBS had OOPE of about
$300 per year more than those without a cancer his-
tory (personal communication with K. Hutchins,
Research Data Assistance Center, Centers for Medi-
care and Medicaid Services, 2001, unpublished).
Finally, the expenditure data used for this study
were from 1995, and therefore provide information
on OOPE for a time period before the recent large
increase in OOPE for prescription drugs among
older Medicare beneﬁciaries [45]. Further research
using more recent OOPE data is necessary to deter-
mine how recent trends in OOPE, in general, and
among older patients receiving cancer treatment, in
particular, have affected the quantity and distribu-
tion of OOPE for medical care among older Amer-
icans. Our study provides representative baseline
information to which future studies of OOPE can
be compared.
This study of a nationally representative sample
of older Americans suggests that undergoing treat-
ment for cancer may result in signiﬁcant OOPE for
medical care presumably related both to the treat-
ment itself and to complications from the underly-
ing cancer and its treatment. Although a new beneﬁt
within the Medicare program to cover prescription
medications would relieve a signiﬁcant burden of
OOPE for older Americans, those undergoing can-
cer treatment may still face signiﬁcant out-of-pocket
costs related to both acute care and community-
based long-term care services. Low-income older
Americans may face an especially daunting ﬁnancial
burden if cancer treatment is required, because a
signiﬁcant portion of their yearly income may be
necessary to pay for treatment-related medical
costs. Future research should examine how recent
increases in prescription medication use and costs
among elderly individuals has affected the level of
their out-of-pocket spending and the possibility that
signiﬁcant OOPE related to cancer treatment may
lead older individuals to forgo cancer therapies that
might provide signiﬁcant beneﬁt.
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